← 返回前沿论文

NSCLC 肿瘤病灶中三级淋巴结构相关免疫浸润与 TIL 产品低肿瘤反应性的相关性

英文原题:Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.

PubMed 2024/08/22(内容时间) Oncoimmunology Q1 · IF 6.2(JCR 2025)

研究概要

NSCLC肿瘤中免疫细胞浸润的组成与扩增TIL产物的功能性相关。

中文摘要

过继转移TIL(肿瘤浸润淋巴细胞)(TIL 疗法)已被证明对治疗实体癌高度有效,包括非小细胞肺癌(NSCLC)。然而,由于未知原因,并非所有患者都能从该疗法中获益。因此,确定与自体 TIL 产品高肿瘤反应性相关的标志物是实现更好定制免疫疗法的关键。我们质疑免疫细胞浸润的组成是否与扩增 TIL 产品的肿瘤反应性相关。对 26 例早期和 20 例晚期 NSCLC 肿瘤病灶的免疫细胞浸润进行无偏流式细胞术分析,用于与 T 细胞分化和活化状态、以及所生成 TIL 产品的扩增率和抗肿瘤反应进行相关性分析。肿瘤免疫浸润的组成在患者之间高度可变。Spearman 秩相关揭示,高 B 细胞浸润与患者扩增 TIL 产品的肿瘤反应性呈负相关,后者定义为暴露于自体肿瘤消化液后的细胞因子产生。深入分析揭示,具有高 B 细胞浸润的肿瘤病灶含有三级淋巴结构(TLS)相关的免疫浸润,包括 BCL6 + 抗体分泌 B 细胞、IgD + BCL6 + B 细胞和 CXCR5 + BLC6 + CD4 + T 细胞,以及更高比例的初始 CD8 + T 细胞。总之,NSCLC 肿瘤中免疫细胞浸润的组成与扩增 TIL 产品的功能性相关。我们的发现因此可能有助于改善 TIL 疗法的患者选择。

展开英文摘要原文

Adoptive transfer of tumor infiltrating lymphocytes (TIL therapy) has proven highly effective for treating solid cancers, including non-small cell lung cancer (NSCLC). However, not all patients benefit from this therapy for yet unknown reasons. Defining markers that correlate with high tumor-reactivity of the autologous TIL products is thus key for achieving better tailored immunotherapies. We questioned whether the composition of immune cell infiltrates correlated with the tumor-reactivity of expanded TIL products. Unbiased flow cytometry analysis of immune cell infiltrates of 26 early-stage and 20 late-stage NSCLC tumor lesions was used for correlations with the T cell differentiation and activation status, and with the expansion rate and anti-tumor response of generated TIL products. The composition of tumor immune infiltrates was highly variable between patients. Spearman's Rank Correlation revealed that high B cell infiltration negatively correlated with the tumor-reactivity of the patient's expanded TIL products, as defined by cytokine production upon exposure to autologous tumor digest. In-depth analysis revealed that tumor lesions with high B cell infiltrates contained tertiary lymphoid structure (TLS)-related immune infiltrates, including BCL6 + antibody-secreting B cells, IgD + BCL6 + B cells and CXCR5 + BLC6 + CD4 + T cells, and higher percentages of na ve CD8 + T cells. In conclusion, the composition of immune cell infiltrates in NSCLC tumors associates with the functionality of the expanded TIL product. Our findings may thus help improve patient selection for TIL therapy.

论文信息

作者
Castenmiller SM、Kanagasabesan N、Guislain A、Nicolet BP、van Loenen MM、Monkhorst K、Veenhof AAFA、Smit EF
单位
Sanquin Blood Supply, Division Research Immunotherapy, and Landsteiner Laboratory and Department of Experimental Immunology, Amsterdam University Medical Center, Amsterdam, Netherlands.Netherlands
文献类型
非美国政府资助研究
期刊
Oncoimmunology2024
原文标识
PubMed 39188755 · DOI 10.1080/2162402X.2024.2392898